Related Experiment Videos
Topical mitomycin-C for partially excised conjunctival squamous cell carcinoma
Joseph Frucht-Pery1, Yaacov Rozenman, Jacob Pe'er
1Department of Ophthalmology, Hadassah University Hospital, P.O. Box 12000, Jerusalem, Israel. fruchtpery@md.huji.ac.il
Ophthalmology
|March 5, 2002
Summary
Topical mitomycin-C (MMC) effectively treats residual conjunctival squamous cell carcinoma (SCC) after surgery. Follow-up showed no recurrence, with manageable side effects like hyperemia.
Area of Science:
- Ophthalmology
- Oncology
- Dermatology
Background:
- Conjunctival squamous cell carcinoma (SCC) can recur after incomplete excision.
- Topical chemotherapy agents are explored for managing residual ocular surface tumors.
Observation:
- A retrospective case series evaluated five patients with incompletely excised conjunctival SCC.
- Patients received topical mitomycin-C (MMC) at 0.02% or 0.04% for 14-day cycles.
Findings:
- Histologic examination of excised post-treatment tissue revealed no malignant cells in any patient.
- No tumor recurrence was observed during 18 to 37 months of follow-up.
- Mild to moderate conjunctival hyperemia was the primary complication, resolving after treatment cessation.
Implications:
- Topical MMC appears to be an effective adjuvant therapy for residual conjunctival SCC.
- Further long-term studies are warranted to confirm efficacy and safety profiles.